Astaxanthin Reduces Exercising Heart Rate.

NCT05282355 | Completed

• 1 other identifier: AX2021
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 1

Brief Summary

Briefly, this study involved 2 trials: baseline (Trial 1) and post-astaxanthin intervention (Trial 2). Both trials included participants completing a graded exercise test while connected to a metabolic cart, to measure cardiorespiratory measures. Between trials, participants were supplemented with either 12 mg of astaxanthin or placebo for 4 weeks. It was hypothesized astaxanthin supplementation would increase rates of fat oxidation, while decreasing carbohydrate oxidation and blood lactate accumulation.

Conditions

Metabolic Flexibility

Keywords

substrate oxidation; lactate; supplement

Outcome Measures

Primary Outcomes (1)

• Changes to substrate oxidation rates

  Substrate oxidation rates reflect cellular utilization of carbohydrates and lipids at rest and during exercise. If changes exist from astaxanthin supplementation, they would manifest themselves likely via increases to rates of fat oxidation at all stages and a subsequent decrease in carbohydrate oxidation rates at each stage.

  Up to 4 weeks

Study Arms (2)

Astaxanthin

EXPERIMENTAL

The astaxanthin group received 12 mg/day of astaxanthin. Each capsule contained 6 mg of astaxanthin and sunflower oil, and each subject ingested one capsule in the morning and one in the evening.

Dietary Supplement: Astaxanthin

Placebo

PLACEBO COMPARATOR

The placebo group ingested two capsules per day, one in the morning and one in the evening. Each capsule contained sunflower oil and mimicked the size and appearance of the astaxanthin supplement.

Dietary Supplement: Placebo

Interventions

Astaxanthin DIETARY_SUPPLEMENT

Our aim was to examine the impact astaxanthin would have, if any, on markers of metabolic flexibility in overweight individuals in comparison to a placebo.

Astaxanthin

Placebo DIETARY_SUPPLEMENT

To have adequately test the effects of astaxanthin, we provided one group a placebo matched in appearance and taste.

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Free of any cardiometabolic disease medication
• Classified as overweight - body fat % ≥ 20% (M) and ≥ 25% (F)
• Exclude dietary supplements for 2 weeks prior to start of study

You may not qualify if:

• If there is a chance of pregnancy
• body fat % \< 20% (M) and \< 25% (F)

Sponsors & Collaborators

• University of North Alabama: lead

Study Sites (1)

University of North Alabama, Department of Kinesiology

Florence, Alabama, 35630, United States

Location

MeSH Terms

Interventions

astaxanthine

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Participants were blinded to either the supplement or placebo. The capsules were identical in appearance and size. Blinding was accomplished via an investigator not directly involved with data collection.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2022
• First Posted: March 16, 2022
• Study Start: May 12, 2021
• Primary Completion: July 2, 2021
• Study Completion: July 2, 2021
• Last Updated: March 16, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)